Equine Eye Expansion EyeQ Equine Amniotic Eye Drops launch signals Vetrix expanding into equine regenerative ophthalmology, presenting a clear entry point with clinics treating horse injuries. Target customers: equine veterinary practices, ophthalmologists, and large-animal centers; opportunity to upsell BioSIS and VetiVax products to these clinics for comprehensive eye and oncology care; propose distributor partnerships and co-branded campaigns.

Regenerative Medicine Leader Vetrix positions itself as a world supplier of veterinary regenerative products including VetiVax autologous immunotherapy and BioSIS surgical products, offering clinics a full suite for injured and oncologic patients; sales angle: emphasize outcomes, clinical evidence, and training support to drive adoption among surgical and oncology departments; potential to expand into partner networks across regions.

Small Team Growth With a lean team, Vetrix may need distribution or channel partnerships to scale; propose a partner program, white-label options, and reseller support; invest in training and marketing automation to enable partners to generate and close leads for BioSIS, VetiVax, and EyeQ.

Marketing and Outreach The tech stack shows active digital marketing with SharpSpring, DoubleClick, SEO; there is opportunity to scale inbound via specialized content on regenerative medicine, amnion-based therapies, and oncologic care; recommended actions include targeted campaigns to veterinary surgeons, retargeting, webinars, and case studies to accelerate pipeline.

Global Market Potential The claim of being a leading global provider, combined with a low revenue bracket, suggests high growth potential in international markets; identify distributor opportunities in regions with rising adoption of regenerative veterinary therapies; align with partnerships to expand manufacturing and regulatory readiness to capture global demand.